Vertex Pharmaceuticals Incorporated today announced several updates on the Company’ s type 1 diabetes portfolio. VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of the ...

Vertex plans to conduct two 24-week Phase 3 studies to support approval of the combination of VX-809 and ivacaftor in people with CF ages 12 and older.

Vertex Pharmaceuticals Incorporated VRTX has entered into an agreement to acquire ViaCyte, a private cellular therapy company, to accelerate the development of the VX-880 program in type I diabetes.

The cell therapy in VX-264 is zimislecel (formerly VX-880). A separate Vertex program is evaluating zimislecel as a “naked” cell therapy — without encapsulation in a protective medical device.